Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab

High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients

Dwyer, CM
Jokubaitis, VG
Stankovich, J
Baker, J
Haartsen, J
Butzkueven, H
Cartwright, A
Shuey, N
Fragoso, YD
Rath, L
Skibina, O
Fryer, K
Butler, E
Coleman, J
MacIntrye, J
Macdonell, R
van der Walt, A

April 2021

Aims: To retrospectively assess factors associated with John Cunningham virus (JCV) seroconversion i...

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients

van Kempen, Z. L.E.
Leurs, C. E.
de Vries, A.
Vennegoor, A.
Rispens, T.
Wattjes, M. P.
Killestein, J.

September 2017

Background and purpose: Infection with the John Cunningham virus (JCV) is required for the developme...

Luca Prosperini
Nicola de Rossi
Cristina Scarpazza
Lucia Moiola
Mirco Cosottini
Simonetta Gerevini
Ruggero Capra
Italian PML study group

January 2016

The monoclonal antibody natalizumab (NTZ) is a highly effective treatment for patients with multiple...

Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab

Sgarlata, Eleonora
Chisari, Clara Grazia
D'Amico, Emanuele
Millefiorini, Enrico
Patti, Francesco

January 2020

Natalizumab (NTZ) can be associated with an opportunistic infection, progressive multifocal leukoenc...

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab : a cross-sectional and longitudinal study

Jilek, Samantha
Jaquiéry, Emilie
Hirsch, Hans H.
Lysandropoulos, Andreas
Canales, Mathieu
Guignard, Laurence
Schluep, Myriam
Pantaleo, Giuseppe
Du Pasquier, Renaud A.

January 2010

Natalizumab is used to prevent relapses and progression of disability in patients with multiple scle...

UNUSUAL DETERIORATION IN A PATIENT WITH MULTIPLE SCLEROSIS ON NATALIZUMAB THERAPY

Thomas Gattringer Md
Christian Enzinger Md
Michael Khalil
Petra Schwingenschuh
Alexander Moser Md
Winfried Graninger Md
Christina Ernst Msc
Johannes Haybaeck Md
Franz Fazekas Md
Neurol Neuroimmunol

September 2016

Natalizumab is an effective treatment in patients with highly active relapsing-remitting multiple sc...

Natalizumab in Multiple Sclerosis: Long-Term Management

Marinella Clerico

April 2017

Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multip...

Best practice in the use of natalizumab in multiple sclerosis

Óscar Fernández

March 2013

Natalizumab is approved for the treatment of patients with relapsing–remitting multiple sclerosis wh...

Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.

Marco Iannetta
Maria Antonella Zingaropoli
Anna Bellizzi
Manuela Morreale
Simona Pontecorvo
Alessandra D'Abramo
Alessandra Oliva
Elena Anzivino
Sara Lo Menzo
Claudia D'Agostino
Claudio Maria Mastroianni
Enrico Millefiorini
Valeria Pietropaolo
Ada Francia
Vincenzo Vullo
Maria Rosa Ciardi

January 2016

The anti-CD49d monoclonal antibody natalizumab is currently an effective therapy against the relapsi...

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab

Roberta Antonia Diotti
Ruggero Capra
Lucia Moiola
Valeria Caputo
Nicola De Rossi
Francesca Sangalli
Vittorio Martinelli
Roberto Burioni
Massimo Clementi
Nicasio Mancini

May 2016

The association between natalizumab and progressive multifocal leukoencephalopathy (PML) is establis...

Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy

Sormani M. P.
De Stefano N.

January 2014

The infusion of 300 mg of natalizumab every 4 weeks is an effective therapy for reducing disease act...

Natalizumab affects T-Cell phenotype in multiple sclerosis: Implications for JCV reactivation

Iannetta M.
Zingaropoli M. A.
Bellizzi A.
Morreale M.
Pontecorvo S.
D'Abramo A.
Oliva A.
Anzivino E.
Lo Menzo S.
D'Agostino C.
Mastroianni C. M.
Millefiorini E.
Pietropaolo V.
Francia A.
Vullo V.
Ciardi M. R.

January 2016

The anti-CD49d monoclonal antibody natalizumab is currently an effective therapy against the relapsi...

JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.

Lanzillo R
Liuzzi R
Vallefuoco L
Moccia M
Amato L
Vacca G
Vacchiano V
Portella G
Brescia Morra V

January 2014

Natalizumab-treated patients have a higher risk of developing progressive multifocal leukoencephalop...

Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients

Luiz Henrique da Silva Nali
Lenira Moraes
Maria Cristina Domingues Fink
Dagoberto Callegaro
Camila Malta Romano
Augusto Cesar Penalva de Oliveira

December 2014

Natalizumab is currently one of the best options for treatment of patients with Multiple Sclerosis w...

JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients

S. Delbue
F. Elia
C. Carloni
V. Pecchenini
D. Franciotta
M. Gastaldi
E. Colombo
L. Signorini
S. Carluccio
A. Bellizzi
R. Bergamaschi
P. Ferrante

December 2015

The risk of developing progressive multifocal leukoencephalopathy (PML), as a consequence of infecti...

High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients

Dwyer, CM
Jokubaitis, VG
Stankovich, J
Baker, J
Haartsen, J
Butzkueven, H
Cartwright, A
Shuey, N
Fragoso, YD
Rath, L
Skibina, O
Fryer, K
Butler, E
Coleman, J
MacIntrye, J
Macdonell, R
van der Walt, A

April 2021

Aims: To retrospectively assess factors associated with John Cunningham virus (JCV) seroconversion i...

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients

van Kempen, Z. L.E.
Leurs, C. E.
de Vries, A.
Vennegoor, A.
Rispens, T.
Wattjes, M. P.
Killestein, J.

September 2017

Background and purpose: Infection with the John Cunningham virus (JCV) is required for the developme...

Luca Prosperini
Nicola de Rossi
Cristina Scarpazza
Lucia Moiola
Mirco Cosottini
Simonetta Gerevini
Ruggero Capra
Italian PML study group

January 2016

The monoclonal antibody natalizumab (NTZ) is a highly effective treatment for patients with multiple...

Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab

Sgarlata, Eleonora
Chisari, Clara Grazia
D'Amico, Emanuele
Millefiorini, Enrico
Patti, Francesco

January 2020

Natalizumab (NTZ) can be associated with an opportunistic infection, progressive multifocal leukoenc...

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab : a cross-sectional and longitudinal study

Jilek, Samantha
Jaquiéry, Emilie
Hirsch, Hans H.
Lysandropoulos, Andreas
Canales, Mathieu
Guignard, Laurence
Schluep, Myriam
Pantaleo, Giuseppe
Du Pasquier, Renaud A.

January 2010

Natalizumab is used to prevent relapses and progression of disability in patients with multiple scle...

UNUSUAL DETERIORATION IN A PATIENT WITH MULTIPLE SCLEROSIS ON NATALIZUMAB THERAPY

Thomas Gattringer Md
Christian Enzinger Md
Michael Khalil
Petra Schwingenschuh
Alexander Moser Md
Winfried Graninger Md
Christina Ernst Msc
Johannes Haybaeck Md
Franz Fazekas Md
Neurol Neuroimmunol

September 2016

Natalizumab is an effective treatment in patients with highly active relapsing-remitting multiple sc...

Natalizumab in Multiple Sclerosis: Long-Term Management

Marinella Clerico

April 2017

Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multip...

Best practice in the use of natalizumab in multiple sclerosis

Óscar Fernández

March 2013

Natalizumab is approved for the treatment of patients with relapsing–remitting multiple sclerosis wh...

Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.

Marco Iannetta
Maria Antonella Zingaropoli
Anna Bellizzi
Manuela Morreale
Simona Pontecorvo
Alessandra D'Abramo
Alessandra Oliva
Elena Anzivino
Sara Lo Menzo
Claudia D'Agostino
Claudio Maria Mastroianni
Enrico Millefiorini
Valeria Pietropaolo
Ada Francia
Vincenzo Vullo
Maria Rosa Ciardi

January 2016

The anti-CD49d monoclonal antibody natalizumab is currently an effective therapy against the relapsi...

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab

Roberta Antonia Diotti
Ruggero Capra
Lucia Moiola
Valeria Caputo
Nicola De Rossi
Francesca Sangalli
Vittorio Martinelli
Roberto Burioni
Massimo Clementi
Nicasio Mancini

May 2016

The association between natalizumab and progressive multifocal leukoencephalopathy (PML) is establis...

Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy

Sormani M. P.
De Stefano N.

January 2014

The infusion of 300 mg of natalizumab every 4 weeks is an effective therapy for reducing disease act...

Natalizumab affects T-Cell phenotype in multiple sclerosis: Implications for JCV reactivation

Iannetta M.
Zingaropoli M. A.
Bellizzi A.
Morreale M.
Pontecorvo S.
D'Abramo A.
Oliva A.
Anzivino E.
Lo Menzo S.
D'Agostino C.
Mastroianni C. M.
Millefiorini E.
Pietropaolo V.
Francia A.
Vullo V.
Ciardi M. R.

January 2016

The anti-CD49d monoclonal antibody natalizumab is currently an effective therapy against the relapsi...

JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.

Lanzillo R
Liuzzi R
Vallefuoco L
Moccia M
Amato L
Vacca G
Vacchiano V
Portella G
Brescia Morra V

January 2014

Natalizumab-treated patients have a higher risk of developing progressive multifocal leukoencephalop...

Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients

Luiz Henrique da Silva Nali
Lenira Moraes
Maria Cristina Domingues Fink
Dagoberto Callegaro
Camila Malta Romano
Augusto Cesar Penalva de Oliveira

December 2014

Natalizumab is currently one of the best options for treatment of patients with Multiple Sclerosis w...

JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients

S. Delbue
F. Elia
C. Carloni
V. Pecchenini
D. Franciotta
M. Gastaldi
E. Colombo
L. Signorini
S. Carluccio
A. Bellizzi
R. Bergamaschi
P. Ferrante

December 2015

The risk of developing progressive multifocal leukoencephalopathy (PML), as a consequence of infecti...

High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients

Dwyer, CM
Jokubaitis, VG
Stankovich, J
Baker, J
Haartsen, J
Butzkueven, H
Cartwright, A
Shuey, N
Fragoso, YD
Rath, L
Skibina, O
Fryer, K
Butler, E
Coleman, J
MacIntrye, J
Macdonell, R
van der Walt, A

April 2021

Aims: To retrospectively assess factors associated with John Cunningham virus (JCV) seroconversion i...

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients

van Kempen, Z. L.E.
Leurs, C. E.
de Vries, A.
Vennegoor, A.
Rispens, T.
Wattjes, M. P.
Killestein, J.

September 2017

Background and purpose: Infection with the John Cunningham virus (JCV) is required for the developme...

Luca Prosperini
Nicola de Rossi
Cristina Scarpazza
Lucia Moiola
Mirco Cosottini
Simonetta Gerevini
Ruggero Capra
Italian PML study group

January 2016

The monoclonal antibody natalizumab (NTZ) is a highly effective treatment for patients with multiple...

Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab

Abstract

Extracted data

Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab

Abstract

Extracted data

Related items

Related items